Pharmacokinetics and pharmacodynamics of newer fluoroquinolones.
about
In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureusResponse of complicated methicillin-resistant Staphylococcus aureus endocarditis to the addition of trovafloxacin.Applications of flow cytometry to clinical microbiology.A focus on intra-abdominal infections.The use of fluoroquinolones for companion animal antimicrobial therapy.Clinical use of fluoroquinolones in children.2013 WSES guidelines for management of intra-abdominal infections.Fluoroquinolone adverse effects and drug interactions.WSES consensus conference: Guidelines for first-line management of intra-abdominal infections.The new fluoroquinolones: A critical reviewThe management gram-negative bacterial haematogenous vertebral osteomyelitis: a case series of diagnosis, treatment and therapeutic outcomes.Species distribution and antimicrobial susceptibility of gram-negative aerobic bacteria in hospitalized cancer patients.In-vitro Antimycoplasmal Activity of Triclosan in Combination with Fluoroquinolones against Five mycoplasma Species.New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.Fluoroquinolone disposition: identification of the contribution of renal secretory and reabsorptive drug transporters.Development of levofloxacin inhalation solution to treat Pseudomonas aeruginosa in patients with cystic fibrosisLevofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis.Clinical pharmacokinetics of inhaled antimicrobials.Review of Properties and Analytical Methods for the Determination of Norfloxacin.Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis.Topoisomerase II and IV quinolone resistance-determining regions in Stenotrophomonas maltophilia clinical isolates with different levels of quinolone susceptibility.Wolbachia pipientis growth kinetics and susceptibilities to 13 antibiotics determined by immunofluorescence staining and real-time PCR.Pharmacokinetics and bioavailability of flumequine in blunt snout bream (Megalobrama amblycephala) after intravascular and oral administrations.Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model.Binding characteristics of fluoroquinolones to synthetic levodopa melanin.Determinant of the distribution volume at steady state for novel quinolone pazufloxacin in rats.Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci.Silver(I) complexes as precursors to produce silver nanowires: structure characterization, antimicrobial activity and cell viability.Ubiquitous Nature of Fluoroquinolones: The Oscillation between Antibacterial and Anticancer Activities.Mass spectrometic study of speciation in aluminium-fluoroquinolone solutions.A retrospective analysis of pharmacokinetic/pharmacodynamic indices as indicators of the clinical efficacy of ciprofloxacin.Isocratic Resolution of Fluoroquinolone-Based Antibiotics on the Phenylethyl-Bonded Phase under Nonaqueous Elution: A Consideration of the Separation Mechanism.Determination of the presence and pharmacokinetic profile of ciprofloxacin by TLC and HPLC method respectively in broiler chicken after single oral administration
P2860
Q28368317-C2C9631F-9B78-4B80-809D-97ECA6809D96Q28379074-F803D1C5-74E3-47C3-A4FE-1EC250DCE9F6Q31372845-24F7F8F1-2B9C-408A-B9C6-94A70660B01AQ33555394-1893F753-8022-4532-9709-7CD0D8505771Q33763449-D4FB7039-8DFA-4363-A3C6-7C5E7CDD830AQ33875128-3C2228F2-4552-4C83-A6FF-37BE33AD5ECBQ33985235-CE858188-A658-42D6-9540-AE764DA35EF5Q34321150-08DA7FFF-10D5-41E2-B7DD-88983F98F9EFQ34408447-38DD3F87-4932-44BC-88B8-9E768718C190Q34541183-5305A07C-E07A-49F7-AD16-0F4A254EB7D7Q35649595-79B8723E-DDDF-4DAB-AABA-76B82825230EQ37064474-DBFB1F62-C29D-4EC2-82F8-2D661C572403Q37126210-2D4D3AAE-C91B-482F-95E0-EB9A0B13D2DBQ37268241-E608B7FB-3150-4F3C-9BEA-B8274C99522AQ37346929-F39C1C1B-6844-4DEB-B46D-50182F8BB88BQ37995676-54C76899-D602-4F4B-9470-EAA7EDE253BFQ38170953-351810DC-54F8-4475-B0B4-E53C5D361A8CQ38270626-88D17660-F932-4035-B9BA-E5C36B04F6F2Q38367260-0D9E43E4-7D29-44FA-B510-08B92D46EC8BQ38591662-DD97F504-0865-4B8A-A92C-59603B0CD5A7Q39469535-26EFAB5D-FA6A-4A57-A8BE-2C0C7EA64D5EQ39652979-FD2A1652-A789-434F-8246-DFB0A2E9D438Q39746369-3C182196-B299-432F-9C99-6BC65F3057C6Q40495171-E805F6F2-7E1E-4B2D-8BFF-DA0C25CCDD65Q40621865-AC3A6F37-D731-42A9-A641-A530DCBD7A8BQ41915304-8B0AD7BE-9FE2-41FF-92C3-60E2DD5CD0F1Q44160444-0B83E0E1-C4AB-447E-B52B-9B5F333A1609Q44959765-9932215C-9740-4733-9CAE-1280016226F0Q45752554-E65A9D8E-80E1-43E3-BFF2-DDB22B08D9FAQ47101582-AFD05C46-A047-4C88-93EA-5F7E1AD3A7A0Q47334609-EC52AE0A-792C-42FB-B053-B9BFC4605102Q52081442-7C98C5F2-C524-4227-8141-93B45DBEF1A9Q55399889-2CE285DF-29C6-431F-9786-01EFFC68C64FQ57930525-34881E94-49DA-4627-A292-DAC755C8D884
P2860
Pharmacokinetics and pharmacodynamics of newer fluoroquinolones.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Pharmacokinetics and pharmacodynamics of newer fluoroquinolones.
@en
type
label
Pharmacokinetics and pharmacodynamics of newer fluoroquinolones.
@en
prefLabel
Pharmacokinetics and pharmacodynamics of newer fluoroquinolones.
@en
P1476
Pharmacokinetics and pharmacodynamics of newer fluoroquinolones.
@en
P2093
P304
P356
10.1093/CLINIDS/23.SUPPLEMENT_1.S19
P407
P478
23 Suppl 1
P577
1996-12-01T00:00:00Z